Rights & Issues Investment Trust (RIII) Share Price, News & Analysis

Company Overview

Rights and Issues Investment Trust Public Limited Company is a self-managed investment trust. The firm invests in public equity markets of the United Kingdom. It invests in stocks of small-cap companies. The firm benchmarks the performance of its portfolio against the FTSE All share index. Rights and Issues Investment Trust Public Limited Company was founded in 1963 and is based in London, United Kingdom.

Key Stats

• Today's Range: 2,150.77 to 2,198.93
• 50-Day Range: 1,865 to 2,215
• 52-Week Range: 1,670 to 2,500
• Volume: 3,628 shs
• Average Volume: 4,553 shs
• Market Capitalization: £105.21 million
• P/E Ratio: 6.92
• Dividend Yield: 1.98%
• Price Target: N/A
• Consensus Rating: N/A

RIII Stock Analysis - Frequently Asked Questions

How have RIII shares performed this year?

Rights & Issues Investment Trust's stock was trading at GBX 2,378.49 on January 1st, 2025. Since then, RIII stock has decreased by 8.5% and is now trading at GBX 2,176.29.

How were Rights & Issues Investment Trust's earnings last quarter?

Rights & Issues Investment Trust (LON:RIII) released its quarterly earnings data on Friday, February, 21st. The company reported $42.10 earnings per share for the quarter. Rights & Issues Investment Trust had a net margin of 93.27% and a trailing twelve-month return on equity of 12.60%.

How do I buy shares of Rights & Issues Investment Trust?

Shares of RIII stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Rights & Issues Investment Trust own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rights & Issues Investment Trust investors own include Milestone Pharmaceuticals (MIST), Ovintiv (OVV), SIG (SHI), Allena Pharmaceuticals (ALNA), Alpine Immune Sciences (ALPN), Affiliated Managers Group (AMG) and Aravive (ARAV).

Company Calendar

• Last Earnings: 2/21/2025
• Today: 7/15/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Financial Services
• Industry: Asset Management
• Sub-Industry: N/A
• Current Symbol: LON:RIII
• CIK: N/A
• Web: www.maitlandgroup.com
• Phone: +44-1245-398984
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX 314.53
• Trailing P/E Ratio: 6.92
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £15.28 million
• Net Margins: 93.27%
• Pretax Margin: N/A
• Return on Equity: 12.60%
• Return on Assets: 1.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.38
• Quick Ratio: 60.63

Sales & Book Value

• Annual Sales: £16.38 million
• Price / Sales: 6.42
• Cash Flow: GBX 179.75 per share
• Price / Cash Flow: 12.11
• Book Value: GBX 2,584.15 per share
• Price / Book: 0.84

Miscellaneous

• Outstanding Shares: 4,834,231
• Free Float: N/A
• Market Cap: £105.21 million
• Optionable: Not Optionable
• Beta: 0.74